Co-authors present the cases of five multiple sclerosis patients who developed COVID-19 infection while taking the oral disease-modifying therapy teriflunomide and continued taking the medication. All five patients had favorable outcomes, with their COVID-19 taking a mild course and without experiencing relapse of their MS.
- Study shows myocarditis linked to COVID-19 not as common as believed
- Water fleas on ‘happy pills’ have more offspring
- Breakthrough quantum-dot transistors create a flexible alternative to conventional electronics
- Losing ground in biodiversity hotspots worldwide
- Positive outlook predicts less memory decline